Document |
Document Title |
WO/2016/072049A1 |
Provided are: a non-ionic photoacid generator containing a sulfonate compound having a high photosensitivity to i lines, exhibiting excellent heat-resistance stability, and exhibiting excellent solubility in a hydrophobic material; and a...
|
WO/2016/065662A1 |
A continuous petroleum sulfonate production method using micro-chemical technology, the method comprising: continuously passing a diluted petroleum fraction and diluted liquid sulfur trioxide through a micro-channel reactor combining a m...
|
WO/2016/069527A1 |
Embodiments of methods for co-production of linear alkylbenzene and oleochemicals from a natural oil are provided. An exemplary method includes fat splitting the natural oil to form a stream comprising free fatty chains. The method inclu...
|
WO/2016/064619A1 |
Disclosed are a variety of amphoteric ester sulfonates of formula 1, including 3-(N,N-dimethyl-cocoylpropylammonio-1-yl)-2-hydroxypropanesu
lfonate. These amphoteric ester sulfonates can be advantageously prepared in high yield and purit...
|
WO/2016/058659A1 |
The invention relates to compositions that are liquid at 20 °C containing at least 90 wt% ammonium salts of secondary paraffin sulfonic acids of the general formula (A), where m and n are mutually independent integers from 0 to 18, and ...
|
WO/2016/060038A1 |
The present invention provides a non-aqueous electrolyte having excellent overcharge prevention performance and being capable of maintaining low internal resistance and high electrical capacitance even after charging and discharging, and...
|
WO/2016/058238A1 |
A method using marine product leftovers to extract taurine, the raw material being the marine product leftovers, the method being formed of impurity removal, washing, pulping, filtration, acid precipitation, alkaline precipitation, decol...
|
WO/2016/058082A1 |
Compounds having a structure of Formula I: (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, Z, X and n are as defined herein, and wherein the compound comprises at least one 18F moiety, are provi...
|
WO/2016/056448A1 |
Provided is a novel protecting-group introducing agent for a hydroxy group and/or a mercapto group that can be introduced and removed under mild conditions. This protecting-group introducing agent, which protects a hydroxy group and/or a...
|
WO/2016/052928A1 |
The present invention relates to an alpha-aminoamide derivative compound and a pharmaceutical composition comprising the same. According to various embodiments of the present invention, provided is a therapeutic agent which can overcome ...
|
WO/2016/047784A1 |
Provided are a novel sulfonium salt having high sensitivity with respect to active energy rays, a photoacid generator comprising the sulfonium salt, and a photosensitive composition containing the photoacid generator. The sulfonium salt ...
|
WO/2016/040226A1 |
In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tau...
|
WO/2016/030790A1 |
Oxime sulfonate compounds of the formula (I), wherein R 1 is O(CO)R 4, COOR 5 or CONR 6R 7; n is 1 or 2; R 2 for example is C 1-C 8alkyl, C 3-C 6cycloalkyl or benzyl; R 3 is for example C 1-C 8alkyl, C 3-C 6cycloalkyl, C 1-C 8haloalkyl, ...
|
WO/2016/031436A1 |
A curable composition that comprises an amide compound, said amide compound being represented by general formula (1) and having a sulfonic acid density of 3.9 meq/g or greater, a cured product of a functional polymer, a stack or device p...
|
WO/2016/031961A1 |
The present invention provides an ionic liquid or plastic crystal comprising anions and cations, said anions including [C(SO2F)3]- and said cations including at least one type selected from the group consisting of 1-ethyl-3-methylimidazo...
|
WO/2016/024434A1 |
The present invention relates to the following: a compound represented by formula [1] or a salt thereof; a fungicidal composition comprising the compound or salt thereof; a method for eliminating plant diseases brought on by plant pathog...
|
WO/2016/017713A1 |
Provided is an oil and water separation device that can easily and inexpensively separate and collect the oil component from a mixed fluid comprising water and oil. This oil and water separation device gravity-filters a mixed fluid compr...
|
WO/2016/017754A1 |
This filter medium for separating a liquid containing water and oil and having a channel for the liquid also has a substrate constituting the channel, and one or more types of nitrogen-containing fluorine-based compounds present on the s...
|
WO/2016/017768A1 |
This hydrophilic oil-repellent complex includes one or more types of nitrogen-containing fluorine compounds, and an inorganic compound that has an electric charge or ionic group. The nitrogen-containing fluorine compound includes, within...
|
WO/2016/017686A1 |
This hydrophilic oil repellent agent includes at least one species of nitrogen-containing fluorine compound. The nitrogen-containing fluorine compound includes, in the molecule thereof, any one hydrophilicity-imparting group selected fro...
|
WO/2015/199100A1 |
The present invention is a zwitterionic compound represented by formula (I): R1 – A+ – X – SO3 –, and an ion conductor containing the zwitterionic compound. In formula (I), R1 represents a C2-20 group that has an ether bond and b...
|
WO/2015/194880A1 |
The present invention relates to a sulfonate-based compound and a method for preparing same.
|
WO/2015/194293A1 |
This lubricant contains a protic ionic liquid having a conjugate acid (B+) and a conjugate base (X-), the ionic liquid is represented by general formula (1), and the conjugate base is one of the conjugate base of sulfonic acid, the conju...
|
WO/2015/189114A1 |
The present invention describes a novel process for preparing 3-chloro-2-vinylphenol which, owing to the chemoselectivity achieved, also allows direct conversion into (3-chloro-2-vinylphenyl)methane- sulphonate.
|
WO/2015/191900A1 |
Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provide...
|
WO/2015/188233A1 |
The present invention broadly relates to a process for preparing fatty acid alkyl esters from fat-containing feedstocks using sulfonated fatty acid catalysts.
|
WO/2015/183343A1 |
The present invention discloses a cyclic process for the production of taurine from ethylene oxide in a high yield of greater than 95% by continuously converting the byproducts of the ammonolysis reaction, sodium ditaurinate and sodium t...
|
WO/2015/178342A1 |
The present invention provides a method for producing a compound represented by general formula (5) (R1-Ar-X, where Ar, X, X', and R1 are as defined in the present specification and claims), the method characterized by reacting an aromat...
|
WO/2015/174471A1 |
An onium salt represented by formula (a). Z-A-W-Y+(R)nX- (a) (In formula (a), Z, A, W, Y, (R)n, and X have the following meanings: Z represents a monovalent organic group having a ring structure provided with a conjugated π electron sys...
|
WO/2015/174215A1 |
An actinic ray-sensitive or radiation-sensitive resin composition comprising a photoacid generator and resin (B), said resin composition comprising, as the photoacid generator, at least photoacid generator (A) represented by general form...
|
WO/2015/161812A1 |
The present invention relates to a compound, more particularly, a sulfobetaine compound having double fatty alcohol polyalkoxy ether chains, which can be used for extraction of hydrocarbons, in particular, crude oil, from an underground ...
|
WO/2015/158157A1 |
Disclosed is a method for cyclically preparing taurine from a hydroxyethyl sulfonic acid alkali metal salt and a vinyl sulfonic acid alkali metal salt. In the method, by-products of an ammonolysis reaction, i.e., disodium taurate and tri...
|
WO/2015/157483A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as rep...
|
WO/2015/151977A1 |
The present invention comprises: a zwitterionic compound represented by formula (I): NC-B1-A+-B2-SO3 [in the formula, A+ represents a C2-40 cationic group which contains one or more nitrogen atoms and has two bonds, B1 represents a C1-10...
|
WO/2015/149638A1 |
Provided are four dabigatran etexilate mesylate new crystalline forms, preparation method thereof and pharmaceutical composition containing the four crystalline forms. The method comprises: dissolving the dabigatran etexilate mesylate in...
|
WO/2015/150390A1 |
The present invention relates to compounds of formula (I) wherein X is N or P; -SO3- is -O-S(O)2 -or -S(O)2-O-; and n and R1 to R5 are defined below, and to their use as additives for electrolyte compositions, in particular in electrolyt...
|
WO/2015/144282A1 |
The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.
|
WO/2015/141504A1 |
The present invention is a radiation-sensitive resin composition containing a radiation-sensitive acid generator and a polymer having a structural unit containing an acid-dissociable group, the radiation-sensitive acid generator containi...
|
WO/2015/137122A1 |
A curable composition, a polymer functional cured product, a water-soluble acrylamide compound, and a method for manufacturing the same, the curable composition including a water-soluble acrylamide monomer represented by general formula ...
|
WO/2015/135360A1 |
The present invention relates to a gossypol aromatic amine Schiff base derivative as shown by general formula (I) and a preparation thereof and a use thereof in pesticides. This type of compound represents a novel and simple type of anti...
|
WO/2015/131829A1 |
The present invention relates to novel M and N crystal forms of dabigatran etexilate mesylate and preparation methods and uses thereof, wherein the X-Ray powder diffractogram of the M crystal form has a characteristic peak at the followi...
|
WO/2015/125572A1 |
A method for producing a thiopyranose compound represented by formula (2), which comprises reacting a compound represented by formula (1) with a sulfur compound. X represents a leaving group; A represents an oxygen atom or a sulfur atom;...
|
WO/2015/124289A1 |
The invention relates to novel compounds having fluoridated terminal groups, to the use thereof as surface-active substances, and to agents containing said compounds.
|
WO/2015/125892A1 |
The present invention provides a compound that is represented by general formula (I) (In the formula, Z represents AA. YÂ 1 represents N or CR1, Y2 represents N or CR2, Y3 represents N or CR3, and Y4 represents N or CR4. One of R1-R4 in...
|
WO/2015/119134A1 |
Provided is novel lithium styrene sulfonate that makes it possible to overcome increases in production costs due to drying under atmospheric pressure or reduced pressure at temperatures of 40ºC or higher and the polymerization of lithiu...
|
WO/2015/117146A1 |
β-Substituted -amino acids, β-substituted γ-amino acid derivatives, and β-substituted γ-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted γ-amino acid derivatives and Î...
|
WO/2015/117147A1 |
β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and...
|
WO/2015/115515A1 |
An aryl sulfonic acid compound represented by formula (A1) or (A2). (In the formulas, Ar1 represents a monovalent C6-20 aromatic group substituted by m number of Z0 and substituted by a fluorine atom; Ar2 represents a divalent C6-20 arom...
|
WO/2015/111654A1 |
An aryl sulfonic acid compound represented by formula (1). (In the formula, Ar1 represents a group represented by formula (2), and Ar2 represents a group represented by formula (3). (in the formula, q represents an integer of 1-4.))
|
WO/2015/110262A1 |
The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention f...
|